| 7.38 0.16 (2.22%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.09 | 1-year : | 10.62 |
| Resists | First : | 7.78 | Second : | 9.09 |
| Pivot price | 6.77  |
|||
| Supports | First : | 6.62 | Second : | 5.9 |
| MAs | MA(5) : | 7.15 |
MA(20) : | 6.69 |
| MA(100) : | 9.09  |
MA(250) : | 10.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 86.6 |
D(3) : | 84.4 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 16.73 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RXST ] has closed below upper band by 13.4%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.68 - 7.71 | 7.71 - 7.74 |
| Low: | 6.93 - 6.97 | 6.97 - 7 |
| Close: | 7.32 - 7.38 | 7.38 - 7.43 |
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Sat, 11 Apr 2026
Needham Maintains RxSight (RXST) Buy Recommendation - MSN
Thu, 09 Apr 2026
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026 - Sahm
Wed, 08 Apr 2026
RxSight's cataract lens adjusted after surgery reaches 300,000 uses - Stock Titan
Thu, 02 Apr 2026
RXST SEC Filings - Rxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 02 Apr 2026
RxSight management joins Needham virtual healthcare event Apr. 16 - Stock Titan
Wed, 25 Feb 2026
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 5,070 (K) |
| Shares Short P.Month | 5,360 (K) |
| EPS | -0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.67 |
| Profit Margin | -29 % |
| Operating Margin | -34.8 % |
| Return on Assets (ttm) | -9.6 % |
| Return on Equity (ttm) | -14 % |
| Qtrly Rev. Growth | -18.9 % |
| Gross Profit (p.s.) | 2.49 |
| Sales Per Share | 3.25 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -7.77 |
| PEG Ratio | 0 |
| Price to Book value | 1.1 |
| Price to Sales | 2.26 |
| Price to Cash Flow | -19.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|